662 Phase I/II study of ipilimumab plus nivolumab combined with sacituzumab govitecan in patients with metastatic cisplatin-ineligible urothelial carcinoma

• Rohit Jain,
• Yuanquan Yang,
• Amir Mortazavi,
• Jingsong Zhang,
• Jasreman Dhillon,
• Youngchul Kim,
• Wenyi Fan,
• Guru P Sonpavde,
• Juskaran Chadha,
• Monica Chatwal,
• Sarah Raymond,
• Erika Saunders,
• Trey Poehlman

Affiliations

Rohit Jain

1H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA

Yuanquan Yang

2The Ohio State University/Pelotonia Institute for Immuno-Oncology, Columbus, OH, USA

Amir Mortazavi

3The Ohio State University, Columbus, OH, USA

Jingsong Zhang

1H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA

Jasreman Dhillon

1H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA

Youngchul Kim

1H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA

Wenyi Fan

1H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA

Guru P Sonpavde

4Advent Health Cancer Institute, Orlando, FL, USA

Juskaran Chadha

1H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA

Monica Chatwal

1H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA

Sarah Raymond

1H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA

Erika Saunders

1H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA

Trey Poehlman

1H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA